The estimated Net Worth of Freddy A. Jimenez is at least $1.48 Milion dollars as of 5 June 2024. Mr Jimenez owns over 9,540 units of Celldex Therapeutics stock worth over $1,476,721 and over the last 3 years he sold CLDX stock worth over $0.
Mr has made over 4 trades of the Celldex Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 9,540 units of CLDX stock worth $99,025 on 5 June 2024.
The largest trade he's ever made was exercising 24,166 units of Celldex Therapeutics stock on 13 February 2024 worth over $93,281. On average, Mr trades about 5,268 units every 129 days since 2021. As of 5 June 2024 he still owns at least 35,464 units of Celldex Therapeutics stock.
You can see the complete history of Mr Jimenez stock trades at the bottom of the page.
Freddy A. Jimenez Esq. is the Sr. VP & Gen. Counsel at Celldex Therapeutics.
Mr Esq is 52, he's been the Sr. VP & Gen. Counsel of Celldex Therapeutics since . There are 18 older and 6 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Freddy's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil oraz Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: